Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398:314-324. http://doi.org/10.1016/S0140-6736(21)00933-8.
Brudno JN, and Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev 34:45-55. http://doi.org/10.1016/j.blre.2018.11.002.
Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ et al (2022) NCCN Guidelines(R) Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw 20:8-19. http://doi.org/10.6004/jnccn.2022.0002.
Cowan DH, Graham RC, Jr., and Baunach D (1975) The platelet defect in leukemia. Platelet ultrastructure, adenine nucleotide metabolism, and the release reaction. J Clin Invest 56:188-200. http://doi.org/10.1172/JCI108067.
Favaloro EJ, and Bonar R (2018) An update on quality control for the PFA-100/PFA-200. Platelets 29:622-627. http://doi.org/10.1080/09537104.2018.1475636.
Foss B, and Bruserud O (2008) Platelet functions and clinical effects in acute myelogenous leukemia. Thromb Haemost 99:27-37. http://doi.org/10.1160/TH07-04-0240.
Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H et al (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110:1392-1397. http://doi.org/10.1161/01.CIR.0000141575.92958.9C.
Ke M, Kang L, Wang L, Yang S, Wang Y, Liu H et al (2021) CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients. J Hematol Oncol 14:90. http://doi.org/10.1186/s13045-021-01101-6.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188-195. http://doi.org/10.1182/blood-2014-05-552729.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25:625-638. http://doi.org/10.1016/j.bbmt.2018.12.758.
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21:207-221. http://doi.org/10.1016/S1470-2045(19)30788-0.
Mikkilineni L, and Kochenderfer JN (2017) Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood 130:2594-2602. http://doi.org/10.1182/blood-2017-06-793869.
Moscardo A, Latorre A, Santos MT, Bonanad S, and Valles J (2015) Platelet function in malignant hematological disorders. Curr Opin Oncol 27:522-531. http://doi.org/10.1097/CCO.0000000000000237.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D et al (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 380:1726-1737. http://doi.org/10.1056/NEJMoa1817226.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-548. http://doi.org/10.1016/S1470-2045(14)70442-5.
Robak M, Trelinski J, and Chojnowski K (2012) Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol 29:3574-3580. http://doi.org/10.1007/s12032-012-0290-0.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z et al (2022) Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol:JCO2101676. http://doi.org/10.1200/JCO.21.01676.
Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J et al (2020) Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies. Biol Blood Marrow Transplant 26:865-875. http://doi.org/10.1016/j.bbmt.2019.11.027.
Ware JA, Clark BA, Smith M, and Salzman EW (1989) Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 73:172-176.
Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6:e521-e529. http://doi.org/10.1016/S2352-3026(19)30115-2.